Nivolumab and Ipilimumab-induced myositis and myocarditis mimicking a myasthenia gravis presentation

Immune-checkpoint inhibitors (ICIs) are novel therapeutic agents that have demonstrated relevant anti-tumor responses in multiple cancer types. They produce a potentiation of the immune response against the cancer by blocking the negative down-regulation of T cells. Checkpoint inhibitor-associated neurological side effects are rare but also potentially life-threatening [1].

Source: Neuromuscular Disorders - November 5, 2019 Category: Neurology Authors: Rafael Valenti-Azcarate, Ines Esparragosa Vazquez, Carlos Toledano Illan, Miguel Angel Idoate Gastearena, Jaime G állego Pérez-Larraya Tags: Case report Source Type: research